Mesothelin Immunotherapy for Cancer: Ready for Prime Time?

Overview

Journal J Clin Oncol

Specialty Oncology

Date 2016 Nov 19

PMID 27863199

Citations 186

Authors

Raffit Hassan

Anish Thomas

Christine Alewine

Dung T Le

Elizabeth M Jaffee

Ira Pastan

Affiliations

Soon will be listed here.

Abstract

Mesothelin is a tumor antigen that is highly expressed in many human cancers, including malignant mesothelioma and pancreatic, ovarian, and lung adenocarcinomas. It is an attractive target for cancer immunotherapy because its normal expression is limited to mesothelial cells, which are dispensable. Several antibody-based therapeutic agents as well as vaccine and T-cell therapies directed at mesothelin are undergoing clinical evaluation. These include antimesothelin immunotoxins (SS1P, RG7787/LMB-100), chimeric antimesothelin antibody (amatuximab), mesothelin-directed antibody drug conjugates (anetumab ravtansine, DMOT4039A, BMS-986148), live attenuated Listeria monocytogenes-expressing mesothelin (CRS-207, JNJ-64041757), and chimeric antigen receptor T-cell therapies. Two antimesothelin agents are currently in multicenter clinical registration trials for malignant mesothelioma: amatuximab in the first-line setting and anetumab ravtansine as second-line therapy. Phase II randomized clinical trials of CRS-207 as a boosting agent and in combination with immune checkpoint inhibition for pancreatic cancer are nearing completion. These ongoing studies will define the utility of mesothelin immunotherapy for treating cancer.

Citing Articles

Mesothelin (MSLN) is Highly Expressed in Triple Negative Breast Cancer and is Associated with Enhanced Cell Proliferation and Proinflammatory Tumor Microenvironment.

Hagerty B, Sato T, Wu R, Ishikawa T, Takabe K Ann Surg Oncol. 2025; .

PMID: 40080368 DOI: 10.1245/s10434-025-17117-y.

Advancing Immunotherapy in Pancreatic Cancer: A Brief Review of Emerging Adoptive Cell Therapies.

Sherpally D, Manne A Cancers (Basel). 2025; 17(4).

PMID: 40002184 PMC: 11853216. DOI: 10.3390/cancers17040589.

Microbiome dysbiosis, neutrophil recruitment and mesenchymal transition of mesothelial cells promotes peritoneal metastasis of colorectal cancer.

Li Q, Xiao Y, Han L, Luo W, Dai W, Fang H Nat Cancer. 2025; .

PMID: 39966610 DOI: 10.1038/s43018-025-00910-9.

Excess shed mesothelin disrupts pancreatic cancer cell clustering to impair peritoneal colonization.

Ewa T, Panchwagh N, Tai C, Avula L, Joseph S, Rudloff M FASEB J. 2024; 38(24):e70247.

PMID: 39673668 PMC: 11646052. DOI: 10.1096/fj.202400446R.

Persistence of activated anti-mesothelin hYP218 chimeric antigen receptor T cells in the tumour is associated with efficacy in gastric and colorectal carcinomas.

Mir S, Venugopalan A, Zhang J, Nair N, Sengupta M, Khanal M Clin Transl Med. 2024; 14(11):e70057.

PMID: 39548594 PMC: 11567854. DOI: 10.1002/ctm2.70057.

References

Le D, Wang-Gillam A, Picozzi V, Greten T, Crocenzi T, Springett G . Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. J Clin Oncol. 2015; 33(12):1325-33. PMC: 4397277. DOI: 10.1200/JCO.2014.57.4244. View

Tozbikian G, Brogi E, Kadota K, Catalano J, Akram M, Patil S . Mesothelin expression in triple negative breast carcinomas correlates significantly with basal-like phenotype, distant metastases and decreased survival. PLoS One. 2014; 9(12):e114900. PMC: 4266616. DOI: 10.1371/journal.pone.0114900. View

Hassan R, Kreitman R, Pastan I, Willingham M . Localization of mesothelin in epithelial ovarian cancer. Appl Immunohistochem Mol Morphol. 2005; 13(3):243-7. DOI: 10.1097/01.pai.00000141545.36485.d6. View

Brockstedt D, Giedlin M, Leong M, Bahjat K, Gao Y, Luckett W . Listeria-based cancer vaccines that segregate immunogenicity from toxicity. Proc Natl Acad Sci U S A. 2004; 101(38):13832-7. PMC: 518841. DOI: 10.1073/pnas.0406035101. View

Zhang Y, Chertov O, Zhang J, Hassan R, Pastan I . Cytotoxic activity of immunotoxin SS1P is modulated by TACE-dependent mesothelin shedding. Cancer Res. 2011; 71(17):5915-22. PMC: 3165076. DOI: 10.1158/0008-5472.CAN-11-0466. View

Gupta A, Hussein Z, Hassan R, Wustner J, Maltzman J, Wallin B . Population pharmacokinetics and exposure-response relationship of amatuximab, an anti-mesothelin monoclonal antibody, in patients with malignant pleural mesothelioma and its application in dose selection. Cancer Chemother Pharmacol. 2016; 77(4):733-43. PMC: 8202971. DOI: 10.1007/s00280-016-2984-z. View

Chang K, Pastan I . Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci U S A. 1996; 93(1):136-40. PMC: 40193. DOI: 10.1073/pnas.93.1.136. View

Illei P, Alewine C, Zahurak M, Cowan M, Montgomery E, Hassan R . Mesothelin Expression in Advanced Gastroesophageal Cancer Represents a Novel Target for Immunotherapy. Appl Immunohistochem Mol Morphol. 2016; 24(4):246-52. PMC: 4821730. DOI: 10.1097/PAI.0000000000000292. View

Hassan R, Sharon E, Thomas A, Zhang J, Ling A, Miettinen M . Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer.... Cancer. 2014; 120(21):3311-9. PMC: 6334650. DOI: 10.1002/cncr.28875. View

10.

Kushitani K, Takeshima Y, Amatya V, Furonaka O, Sakatani A, Inai K . Immunohistochemical marker panels for distinguishing between epithelioid mesothelioma and lung adenocarcinoma. Pathol Int. 2007; 57(4):190-9. DOI: 10.1111/j.1440-1827.2007.02080.x. View

11.

Winter J, Tang L, Klimstra D, Brennan M, Brody J, Rocha F . A novel survival-based tissue microarray of pancreatic cancer validates MUC1 and mesothelin as biomarkers. PLoS One. 2012; 7(7):e40157. PMC: 3391218. DOI: 10.1371/journal.pone.0040157. View

12.

Shimizu A, Hirono S, Tani M, Kawai M, Okada K, Miyazawa M . Coexpression of MUC16 and mesothelin is related to the invasion process in pancreatic ductal adenocarcinoma. Cancer Sci. 2012; 103(4):739-46. PMC: 7659350. DOI: 10.1111/j.1349-7006.2012.02214.x. View

13.

Kreitman R, Hassan R, Fitzgerald D, Pastan I . Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P. Clin Cancer Res. 2009; 15(16):5274-9. PMC: 2754261. DOI: 10.1158/1078-0432.CCR-09-0062. View

14.

Swierczynski S, Maitra A, Abraham S, Iacobuzio-Donahue C, Ashfaq R, Cameron J . Analysis of novel tumor markers in pancreatic and biliary carcinomas using tissue microarrays. Hum Pathol. 2004; 35(3):357-66. DOI: 10.1016/j.humpath.2003.10.012. View

15.

Beatty G, Haas A, Maus M, Torigian D, Soulen M, Plesa G . Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunol Res. 2014; 2(2):112-20. PMC: 3932715. DOI: 10.1158/2326-6066.CIR-13-0170. View

16.

Scales S, Gupta N, Pacheco G, Firestein R, French D, Koeppen H . An antimesothelin-monomethyl auristatin e conjugate with potent antitumor activity in ovarian, pancreatic, and mesothelioma models. Mol Cancer Ther. 2014; 13(11):2630-40. DOI: 10.1158/1535-7163.MCT-14-0487-T. View

17.

Lindenberg L, Thomas A, Adler S, Mena E, Kurdziel K, Maltzman J . Safety and biodistribution of 111In-amatuximab in patients with mesothelin expressing cancers using single photon emission computed tomography-computed tomography (SPECT-CT) imaging. Oncotarget. 2015; 6(6):4496-504. PMC: 4414206. DOI: 10.18632/oncotarget.2883. View

18.

Ordonez N . Value of mesothelin immunostaining in the diagnosis of mesothelioma. Mod Pathol. 2003; 16(3):192-7. DOI: 10.1097/01.MP.0000056981.16578.C3. View

19.

Hassan R, Williams-Gould J, Watson T, Pai-Scherf L, Pastan I . Pretreatment with rituximab does not inhibit the human immune response against the immunogenic protein LMB-1. Clin Cancer Res. 2004; 10(1 Pt 1):16-8. DOI: 10.1158/1078-0432.ccr-1160-3. View

20.

Pastan I, Hassan R, Fitzgerald D, Kreitman R . Immunotoxin therapy of cancer. Nat Rev Cancer. 2006; 6(7):559-65. DOI: 10.1038/nrc1891. View